Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Conteduca V;Wetterskog D;Sharabiani MTA;Grande E;Fernandez-Perez MP;Jayaram A;Salvi S;Castellano D;Romanel A;Lolli C;Casadio V;Gurioli G;Amadori D;Font A;Vazquez-Estevez S;González Del Alba A;Mellado B;Fernandez-Calvo O;Méndez-Vidal MJ;Climent MA;Duran I;Gallardo E;Rodriguez A;Santander C;Sáez MI;Puente J;Gasi Tandefelt D;Wingate A;Dearnaley D;PREMIERE Collaborators;Spanish Oncology Genitourinary Group;Demichelis F;De Giorgi U;‡ Gonzalez-Billalabeitia E;‡ Attard G ‡. ‡These three authors jointly supervised this work as co-senior authors

2017-01-01